Medical device startup exits stealth mode to name CEO, announce $21M in funding
Jupiter Endovascular, a California-based subsidiary of Neptune Medical, has exited stealth mode and announced a new financing round worth $21 million. The company’s primary focus is developing its new Endoportal Control technology and establishing new endovascular procedures that “bring the precision and control of direct surgical access to catheter-based interventions.”
Sonder Capital and other strategic investors contributed to the funding round. The money is expected to help support new clinical research into the safety and effectiveness of treating pulmonary embolisms with Endoportal Control, a new interventional device designed to travel through a patient’s body and provide care from an endovascular access point. Additional funds will also go toward researching new applications for the technology.
Jupiter Endovascular also announced its arrival by naming industry veteran Carl J. St. Bernard the company’s new CEO. St. Bernard has decades of leadership experience in the medical device space, holding leadership roles with CeloNova BioSciences, Tryton Medical, Johnson & Johnson Vision, LifeCell, Cordis, and GE Healthcare.
“The Endoportal Control technology, which leverages Jupiter’s unique and exclusive intellectual property to create a catheter-based device that flexibly navigates through a patient’s vasculature before fixing into a stable position, is designed to give interventionalists the confidence and support they need to deliver a prescribed cardiovascular therapy,” St. Bernard said in a statement. “This represents a generational advance in technology with the potential to revolutionize the treatment of millions of patients worldwide.”
“For decades, the field of catheter-based therapies has been limited by the technological constraints of catheters that lose stability and control within the anatomy,” added Kate Garrett, managing partner at Sonder Capital. “Jupiter Endovascular has developed a revolutionary approach with the potential to overcome these constraints by providing clinicians the precision and control of a surgical approach while maintaining the minimally invasive profile of an endovascular procedure.”
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.